PharmD Signal

Deep dives, evidence grades, and clinical tools, all in one place.

Viloxazine ER Open-Label Extension in Adults: Sustained ADHD Gains, Modest Retention

viloxazine ERQelbreenonstimulantnorepinephrine reuptake inhibitoradult ADHDopen-label extensionlong-term safetypsychopharmacology Psychiatry / Psychopharmacology

Background Information

Viloxazine ER shows long-term efficacy and safety for adult ADHD.

Viloxazine ER offers a nonstimulant option for adult ADHD, detailing its long-term safety and efficacy. During long-term use, viloxazine ER led to significant improvement in ADHD symptoms and quality of life, with 72.3% experiencing mild or moderate adverse events. While the study shows viloxazine's effectiveness, safety issues and high discontinuation rates due to adverse events and other causes remain concerns. Viloxazine ER shows promising improvements for adult ADHD with manageable safety profile over long-term use.

📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report. Cancel anytime.
Subscribe for $8/month → Read this one free →
Free account, no credit card. Includes 1 full deep analysis every month.

Authors: Childress A, Cutler A, Adler L, Fry N, Asubonteng K, Formella A, Rubin J

Citation: Childress A, Cutler A, Adler L, et al. Qelbree (viloxazine extended-release capsules): Final Results of the Long-Term, Phase 3, Open-Label Extension Trial in Adults with ADHD. CNS spectrums. 2024;29(5):479-480. doi:10.1017/S1092852924001263

Article Links: PubMed · Journal / DOI

🎓
Reviewed by a licensed pharmacist
Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.
Accurate and up-to-date information is our highest priority.
If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.
Thanks for the feedback!
🔒
Deep Analysis: Subscribers Only
Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.
Executive Summary
Study Design
Patient Population
Primary Outcomes
Secondary Outcomes & Safety Profile
Pharmacist Implications
Clinical Pearls
Limitations
Controversies & Evidence Gaps
Cost & Logistics
Founding member rate
$8/month. Cancel anytime.

One subscription unlocks this analysis and every other one we publish, plus Practice Signals, PDF reports, and GRADE evidence grades.

Subscribe for $8/month → Read this one free →
Free account, no credit card. Includes 1 full deep analysis every month.
Or $79/year. Founding members keep this rate for as long as they stay subscribed. Cancel anytime from your Account page.